Author

A. Mitrofanova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. A. Hamid· 1 shared A. Ahmad· 1 shared A. Califano· 1 shared A. D. Choudhury· 1 shared A. Fornoni· 1 shared A. Rodriguez-Calero· 1 shared A. S. Kibel· 1 shared A. Sowalsky· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Hamid

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome

M. Ge, J. Molina, J. J. Kim, S. K. Mallela, A. Ahmad, J. Varona Santos, H. Al-Ali, A. Mitrofanova, K. Sharma, F. Fontanesi, S. Merscher, A. Fornoni

This study shows empagliflozin reduces renal lipotoxicity and improves kidney function in experimental Alport syndrome by shifting energy substrates from glucose to fatty acids in podocytes.

bioRxiv · Oct 4, 2022Cell Biology

OncoLoop: A network-based precision cancer medicine framework

A. Vasciaveo, M. Zou, J. M. Arriaga, F. Geraldes de Almeida, E. F. Douglass, M. Shibata, A. Rodriguez-Calero, S. de Brot, A. Mitrofanova, C. W. Chua, C. Karan, R. Realubit, S. Y. Pampou, J. Y. Kim, E. Corey, , C. Abate-Shen

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

bioRxiv · Feb 11, 2022Cancer Biology

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology